Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Should You Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $53.55, but opened at $46.64. Nanobiotix shares last traded at $48.0850, with a volume of 37,689 shares changing hands.

Wall Street Analysts Forecast Growth

NBTX has been the topic of a number of research reports. TD Cowen restated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Guggenheim raised their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Finally, UBS Group lifted their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.67.

Nanobiotix Trading Down 11.0%

The company has a 50-day moving average of $33.49 and a 200 day moving average of $25.90.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. On average, analysts forecast that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current fiscal year.

Institutional Trading of Nanobiotix

Hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Nanobiotix in the 4th quarter worth approximately $390,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the 4th quarter valued at $220,000. Optiver Holding B.V. bought a new position in Nanobiotix in the 3rd quarter valued at $101,000. Finally, Royal Bank of Canada boosted its stake in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.